AION Labs launches CombinAble.AI to design antibodies for therapeutic development [Video]

Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup company CombineAble.AI, which will speed up the development of therapeutics by addressing challenges associated with antibody design. 

CombinAble.AI was formed following an AION Labs startup challenge aimed at developing an AI-based solution for therapeutic antibodies. The company will develop a platform that integrates AI with computational methods for biomolecule simulations aimed at developing new biotherapeutics.  

The process involves leveraging data provided by AION Labs’ pharma partners in addition to publicly available data. 

“Our emphasis is on combining various advanced machine learning models, including large protein language models, molecular dynamics simulations and multi-objective optimization algorithms, integrating them into a single unified solution for targeted antibody discovery, AION Labs’ resources and expertise have been pivotal in shaping our company, providing the material and logistical support to help us refine our scientific strategy, and …